Partial
Partial Aligned
Patient Risk:
Moderate
Summary
Some safety warnings (C. difficile, TIN, bone fracture risk, B12 and magnesium, and general “malignancy not excluded by symptom response”) align with the provided label excerpts for omeprazole + sodium bicarbonate. However, many statements are either not supported by the provided label text (e.g., GERD/ulcer wording, long-term safety/generalization, rebound acid hypersecretion, advice on reassessing therapy, specific alarm-symptom guidance, fracture/infection/CKD claims beyond what’s shown) or are broader than what the label excerpt explicitly states. Several administration-related timing details for capsules and specific stopping/tapering guidance are not supported in the provided excerpts.
Category Scores
Accurate Statements
Long-term PPI use is associated with nutrient absorption problems, including effects on magnesium and vitamin B12 absorption.
Hypomagnesemia and mineral metabolism (5.10) and Cyanocobalamin (Vitamin B-12) deficiency due to long periods of acid-suppressing medications (5.9).
Long-term PPI use has been linked to certain risks.
Multiple warnings/serious adverse reactions described in 5 and 6 (e.g., bone fracture, C. difficile-associated diarrhea, TIN, B12 deficiency, hypomagnesemia).
Long-term PPI use is associated with infection risk due to reduced stomach acidity, including certain gastrointestinal infections such as C. difficile.
PPI therapy may be associated with increased risk of Clostridium difficile-associated diarrhea (5.4); serious adverse reaction listed in 6.
Long-term PPI use has been associated with kidney problems including acute interstitial nephritis.
Acute tubulointerstitial nephritis observed in patients taking PPIs and may occur at any point; discontinue and evaluate (5.2); serious adverse reaction listed in 6.
Some studies have found an increased risk of fractures in long-term PPI users.
Several published observational studies suggest PPI therapy may be associated with an increased risk for osteoporosis-related fractures (5.5); serious adverse reaction listed in 6.
Patients are advised to re-check the need for ongoing PPI therapy if symptoms improve after starting for mild reflux.
Alarm symptoms may indicate conditions that need prompt evaluation rather than adjusting reflux medicine on their own.
Omeprazole works best when taken before meals for many people.
Capsule: take at least one hour before a meal (2.3).
Omeprazole often works best when taken before breakfast.
Using the lowest effective dose for symptom control is usually the goal from a safety standpoint.
Patients should use the lowest dose and shortest duration appropriate for C. difficile risk (5.4).
Alarm symptoms may indicate conditions that need prompt evaluation rather than adjusting reflux medicine on their own.
Presence of gastric malignancy: symptomatic response does not preclude gastric malignancy (5.1).
Unsupported Statements
Omeprazole is commonly prescribed for gastroesophageal reflux disease (GERD).
The label excerpt provided does not explicitly include the phrase “commonly prescribed”; it does indicate indications for GERD/heartburn/EE, but the claim is an unlabel-supported generalization about prescribing frequency.
Omeprazole is commonly prescribed for ulcers.
Unlabel-supported generalization about common prescribing; the label excerpt does include duodenal/benign gastric ulcer indications but not “commonly prescribed.”
Long-term PPIs are generally considered safe for many patients.
No support in the provided label excerpts for a general “generally safe for many patients” statement.
Long-term PPI use has been linked in studies to certain risks.
While the label lists several risks, the broad phrasing “linked in studies” is not directly supported as written by the provided excerpts (though parts of specific risks are supported).
Low magnesium and low vitamin B12 have been reported with prolonged PPI use, especially with prolonged use and other risk factors.
The label excerpt supports possible B12 deficiency with long periods (>3 years) and hypomagnesemia after at least 3 months, but it does not state “especially with prolonged use and other risk factors” as written.
Some studies have found an increased risk of fractures in long-term PPI users.
Supported in substance (observational studies suggest association), but “long-term PPI users” is broader than the label excerpt’s phrasing; score kept as accurate earlier due to close match.
Long-term PPI use is associated with chronic kidney disease.
Not supported by the provided label excerpts; only acute TIN is explicitly described (5.2).
Patients are advised to re-check the need for ongoing PPI therapy if symptoms improve after starting for mild reflux.
No such specific patient advice appears in the provided label excerpts.
Patients are advised to re-check the need for ongoing PPI therapy if they have no history of ulcers, bleeding, or other high-risk complications.
No such specific guidance appears in the provided label excerpts.
Older adults, patients with osteoporosis risk, and patients taking other medicines that can affect bones should be especially careful with long-term omeprazole.
The label excerpt mentions fracture risk (5.5) but does not provide this specific targeted caution wording regarding osteoporosis risk/other bone-affecting medicines.
Patients with kidney disease, low magnesium, or low vitamin B12 should be especially careful with long-term omeprazole.
Label excerpt supports that hypomagnesemia/B12 deficiency may occur (5.9, 5.10) and that TIN requires discontinuation when suspected (5.2), but it does not state this “especially careful” directive tied to kidney disease.
Patients taking medicines with absorption or interaction considerations should be especially careful with long-term omeprazole.
The label lists specific interactions/avoidances (e.g., clopidogrel, St. John’s wort, rifampin, rilpivirine, methotrexate, warfarin), but the provided patient-general directive is not supported as written.
Clinicians generally try to confirm the original indication and whether ongoing therapy is still necessary.
No such general clinician practice statement is present in the provided label excerpts.
“Long term” usually means use beyond the short course often used for initial treatment.
No definition of “long term” is provided in the excerpts (though the label uses durations such as >3 years for B12 deficiency and >8 weeks for EE efficacy).
Many clinicians recommend reassessing PPI use after a planned treatment window and then periodically, especially if symptoms are controlled.
Not present in the provided label excerpts.
Stopping abruptly after long-term daily omeprazole use can cause rebound acid hypersecretion.
No rebound-acid hypersecretion statement appears in the provided label excerpts.
Rebound acid hypersecretion after stopping abruptly can lead to worsening symptoms for some people.
Not present in the provided label excerpts.
A common approach to stopping omeprazole after long-term daily use is to taper or step down gradually and/or switch to as-needed use.
No taper/step-down/as-needed discontinuation approach appears in the provided label excerpts.
The appropriateness of stepping down depends strongly on the reason omeprazole was started.
Not present in the provided label excerpts.
People with a history of ulcer bleeding, severe esophagitis, or other high-risk conditions usually need a clinician-guided plan.
Not present in the provided label excerpts (and “usually need” is not supported).
Omeprazole often works best when taken before breakfast.
The label states capsules should be taken at least one hour before a meal, but does not specify breakfast.
Taking omeprazole properly may reduce the need for higher dosing.
Not supported by the provided label excerpts.
People prescribed omeprazole for an ulcer or bleeding risk should not stop without a plan.
Not present in the provided label excerpts.
Patients with risk factors (older age, bone disease, kidney disease, low magnesium/B12 history) should ask whether monitoring labs or bone risk evaluation is appropriate.
The label mentions considering monitoring/supplementation for hypomagnesemia (5.10) and fracture risk association (5.5), but it does not provide this combined, patient-directed “ask whether…” monitoring/evaluation checklist, nor does it explicitly tie to kidney disease as stated.
Urgent care is recommended for vomiting blood as an alarm symptom while on omeprazole.
No alarm-symptom triage list is present in the provided label excerpts.
Urgent care is recommended for black/tarry stools as an alarm symptom while on omeprazole.
No alarm-symptom triage list is present in the provided label excerpts.
Urgent care is recommended for unexplained weight loss as an alarm symptom while on omeprazole.
No alarm-symptom triage list is present in the provided label excerpts.
Urgent care is recommended for trouble swallowing as an alarm symptom while on omeprazole.
No alarm-symptom triage list is present in the provided label excerpts.
Urgent care is recommended for persistent chest pain as an alarm symptom while on omeprazole.
No alarm-symptom triage list is present in the provided label excerpts.
Urgent care is recommended for anemia as an alarm symptom while on omeprazole.
No alarm-symptom triage list is present in the provided label excerpts.
Contradictions
Important Omissions
Contraindication for patients receiving rilpivirine-containing products (and hypersensitivity to substituted benzimidazoles/components) is not mentioned at all.
Importance:
Moderate
Avoid concomitant use with clopidogrel (and avoid St. John’s wort or rifampin) is not addressed in the provided AI statements, despite being explicitly in the label excerpts.
Importance:
Moderate
Administration instruction details for this specific product are incomplete: capsules should be swallowed intact and not opened; oral suspension has specific feeding timing adjustments for NG/OG tube administration.
Importance:
Moderate
For this product, efficacy for EE longer than 8 weeks is not established and maintenance studies for EE do not extend beyond 12 months; AI text does not reflect these duration boundaries.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Many clinically important label elements are omitted or generalized beyond the provided label excerpts (e.g., contraindication with rilpivirine; specific avoidance with clopidogrel; precise administration constraints). Some safety-risk categories mentioned (C. difficile, TIN, fracture risk, B12/magnesium) align with the label excerpts, but unsupported discontinuation/tapering and alarm-symptom urgent-care triage guidance are not verifiable from the provided labeling.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partial Aligned
Primary Issue
Multiple broad/general statements and discontinuation/alarm-symptom guidance are not supported by the supplied label excerpts; several key contraindication/interaction and specific administration details are omitted.
Suggested Improvement
Restrict claims to the provided label excerpts: (1) include contraindications (rilpivirine-containing products; hypersensitivity) and key interactions to avoid (e.g., clopidogrel; St. John’s wort/rifampin); (2) use label-anchored language for risks (C. difficile-associated diarrhea, acute TIN, osteoporosis-related fractures, B12 deficiency after long periods, hypomagnesemia after >=3 months); (3) replace unsupported stopping/rebound/alarm triage and general “long term” guidance with label-supported duration/administration instructions (e.g., take at least 1 hour before meals; do not open capsules; lowest dose/shortest duration appropriate) and the malignancy caution (symptom response does not preclude gastric malignancy).